Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design
Nano Letters · 25.02.2026 · 26 (7) · 2337-2347
DOI: 10.1021/acs.nanolett.5c05535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nano Letters, online erschienen am 11.02.2026. Verfasst von Ludovica Sciuto und 2 weiteren Autor:innen. Beteiligte Einrichtung: CDL Research, Division LAB, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Holland Top Consortia for Knowledge and Innovation program, European Research Council, HORIZON EUROPE European Research Council.
Abstract (Originalsprache)
CAR T cell therapy represents a leading therapeutic modality in the treatment of hematological cancers. However, conventional ex vivo manufacturing processes are extremely complex, costly, and time-consuming. Hence, in vivo CAR-T cell therapy represents a promising alternative, where T cells are genetically modified directly within the patient. This novel approach requires the careful design of three modular and interdependent nanoscale parameters: CAR architecture, targeted lipid nanoparticle delivery systems, and nucleic acid cargo format. Each component is highly modular, therefore systematic optimization can enhance the safety and efficacy of in vivo CAR T cell generation. Here, we review the molecular and mechanistic principles underlying this therapeutic strategy, emphasizing how these nanoscale design features govern CAR T cell production and functional performance in vivo. Advancing our understanding of these parameters is critical to developing efficient, safe, and clinically translatable in vivo CAR T cell cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CDL Research, Division LAB, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
- Metabolic Diseases Research, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
- Regenerative Medicine Center Utrecht, Uppsalalaan 8, 3584 EA Utrecht, The Netherlands.
- Nanocell Therapeutics BV, Yalelaan 62, 3584 CM Utrecht, The Netherlands.
ORCID-Profile: Raymond M Schiffelers
Förderung
- Health Holland Top Consortia for Knowledge and Innovation program
- European Research Council
- HORIZON EUROPE European Research Council
- Health~Holland
Zitieren
APA
Sciuto, L., Kooijmans, S. A. A., & Schiffelers, R. M. (2026). Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design. Nano Letters, 26(7), 2337-2347. https://doi.org/10.1021/acs.nanolett.5c05535
Vancouver
Sciuto L, Kooijmans SAA, Schiffelers RM. Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design. Nano Letters. 2026;26(7):2337-2347. doi:10.1021/acs.nanolett.5c05535
BibTeX
@article{Sciuto2026,
author = {Sciuto, Ludovica and Kooijmans, Sander A A and Schiffelers, Raymond M},
title = {Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design},
journal = {Nano Letters},
year = {2026},
volume = {26},
number = {7},
pages = {2337--2347},
doi = {10.1021/acs.nanolett.5c05535}
}
EUVIMED